Back to top
more

Lifecore Biomedical, Inc. (LFCR)

(Delayed Data from NSDQ)

$7.41 USD

7.41
116,287

+0.42 (6.01%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $7.43 +0.02 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of -35.71% and 3.95%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dare Bioscience (DARE) delivered earnings and revenue surprises of 3.03% and 101.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lifecore Biomedical (LFCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of 7.41% and 9.64%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal

by Zacks Equity Research

Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.

Zacks Equity Research

Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?

by Zacks Equity Research

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of 100% and 12.78%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of -1,171.43% and 8.80%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 0% and 105.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Immatics (IMTX) delivered earnings and revenue surprises of -2.94% and 28.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Merus N.V. (MRUS) delivered earnings and revenue surprises of 23.26% and 0.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QGEN vs. LFCR: Which Stock Is the Better Value Option?

by Zacks Equity Research

QGEN vs. LFCR: Which Stock Is the Better Value Option?

Zacks Equity Research

Evogene (EVGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 6.25% and 26.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Senesco Technologies Inc. (ELOX) delivered earnings and revenue surprises of -12.94% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for May 15th

by Zacks Equity Research

ARGO, PFSI and LFCR have been added to the Zacks Rank #5 (Strong Sell) List on May 15, 2023.

Zacks Equity Research

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of 6.25% and 10.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 6.47% and 3.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for December 23rd

by Zacks Equity Research

SGRP, LFCR and MD have been added to the Zacks Rank #5 (Strong Sell) List on December 23, 2022.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Beats Q4 Earnings Estimates

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 25% and 1.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?